Ipsen Ireland launches upgraded manufacturing site after €52 million investment
Biopharmaceutical company Ipsen has launched its newly upgraded manufacturing site at Blanchardstown, Dublin. The official site launch follows Ipsen’s recent investment of €52 million to upgrade and expand manufacturing capabilities at the Dublin-based site. The investment has supported the extension and acceleration of vital medicine production which helps patients suffering from both niche cancers and rare diseases in Ireland and across international markets.
The enhanced site has already enabled Ipsen Ireland’s R&D and manufacturing teams to scale their API (active pharmaceutical ingredient) production by 10% this year versus 2021 – supporting increased availability of innovative treatment to improve the quality of life for people living with niche and under-served medical conditions globally.
Ipsen also plans a further €15 million of capital investment in its Blanchardstown site between 2023 and 2026 which will facilitate continued site enhancement from a technology and sustainability perspective. This additional investment is part of Ipsen’s ongoing growth strategy for the Irish market as a biopharmaceutical leader providing transformative care across oncology, rare diseases and neuroscience.
Ipsen CEO David Loew said: “The Irish market plays an important role as part of Ipsen’s international network and Ipsen is committed to continued investment and innovation in Ireland to support improved care for patients across the therapeutic areas we serve – oncology, rare disease, and neuroscience. This new investment in Dublin is a milestone in our ongoing journey of innovation and our growing footprint in Ireland. We hope to continue building Ipsen Ireland as an important pharmaceutical manufacturing and development site within Europe. Now we welcome the continued efforts of the Irish Government to invest in the innovative medicines that will enable Ipsen Ireland to transform even more patients’ lives.”
Commenting on Ipsen’s site launch and investment announcement, Tánaiste Leo Varadkar said: “It’s great to see a biopharmaceutical company which has been here for over 30 years continuing to invest and grow in Ireland, particularly when the goal is to help more patients achieve a better quality of life through its medicines. Ireland is a world hub for life sciences and we’ve worked hard to create a welcoming environment for companies. We also want to be a global leader in innovation. This approach has helped the Government to attract numerous significant investments and it means that Ireland is well-positioned to attract more jobs in the future.”
Tim Shanahan, General Manager & Vice President of Manufacturing for Ipsen Ireland, commented: “We are delighted to officially launch our upgraded Blanchardstown site following recent investments, and we’re proud of the significant impact our manufacturing improvements have already delivered with our treatment output growing by approximately 10% this year compared to last year. Our team of 175 employees here in Dublin are committed to producing life-enhancing care for patients with rare and underserved medical conditions. It’s great that continued investment in our Irish site is enabling our dedicated team to manufacture at pace and scale to help even more patients in need – not only here in Ireland but in various markets across the world.”
In addition to its site upgrade, Ipsen is committed to supporting and building its team of 175 employees in Ireland working across research & development (R&D), manufacturing and commercial operations, to deliver specialty care APIs for patients with rare and underserved conditions. The company has expanded its Blanchardstown workforce by 20% since 2019 and is focused on driving continued research and innovation through its R&D division – growing its team of chemists and analysts by 10% over the past two years.
